Q-omics provides the consensus-scored FOXRED2 profile across patient tissues and cancer cell-line models. FOXRED2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, FOXRED2 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, FOXRED2 RNA expression shows 19,442 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight CESC, HNSC, and ACC as cancer lineages where FOXRED2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FOXRED2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FOXRED2 survival associations across molecular data types. FOXRED2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FOXRED2 RNA expression–survival associations across cancer types. High FOXRED2 expression shows unfavorable associations in ACC, SKCM and MESO, but favorable associations in CESC, LUSC and HNSC. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for FOXRED2 RNA expression.
This table summarizes FOXRED2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for FOXRED2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FOXRED2 shows lower tumor expression in THCA and higher tumor expression in HNSC, COAD, LIHC, LUAD and STAD. The HNSC box plot shows higher FOXRED2 RNA expression in tumor versus normal tissue (log2 FC = +1.159, t-test p < 0.001).
This table shows molecular features associated with FOXRED2 in patient tissues and cancer cell lines. In patient samples, FOXRED2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, FOXRED2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
